Kodai Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kodai Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$5.71M	Buy	+21,159	New	+$5.44M	0.23%	101

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kodai Capital Management's ALNY Position: Q1 2025 in Review

Kodai Capital Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2025: 21,159 shares worth $5.71M. The stake represents 0.23% of the portfolio and ranks #101 among its holdings.

626 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

Kodai Capital Management held 21,159 shares of Alnylam Pharmaceuticals worth $5.71M as of Q1 2025.
Alnylam Pharmaceuticals was a new Kodai Capital Management position in Q1 2025.
Alnylam Pharmaceuticals made up 0.23% of Kodai Capital Management's portfolio in Q1 2025, its #101 holding.
626 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Kodai Capital Management's 13F filing for Q1 2025, filed 15 May 2025.